We performed a panoramic analysis on both human
nonalcoholic steatohepatitis (NASH) microarray data and microarray/
RNA-seq data from various mouse models of
nonalcoholic fatty liver disease NASH/
NAFLD with total 4249 genes examined and made the following findings: (i) human NASH and
NAFLD mouse models upregulate both
cytokines and
chemokines; (ii) pathway analysis indicated that human NASH can be classified into metabolic and immune NASH;
methionine- and
choline-deficient (MCD)+high-fat diet (HFD),
glycine N-methyltransferase deficient (GNMT-KO),
methionine adenosyltransferase 1A deficient (MAT1A-KO), and HFCD (high-fat-
cholesterol diet) can be classified into inflammatory, SAM accumulation,
cholesterol/
mevalonate, and LXR/RXR-
fatty acid β-oxidation
NAFLD, respectively; (iii) canonical and noncanonical
inflammasomes play differential roles in the pathogenesis of NASH/
NAFLD; (iv) trained immunity (TI)
enzymes are significantly upregulated in NASH/
NAFLD; HFCD upregulates TI
enzymes more than
cytokines,
chemokines, and
inflammasome regulators; (v) the MCD+HFD is a model with the upregulation of proinflammatory
cytokines and canonical and noncanonical
inflammasomes; however, the HFCD is a model with upregulation of TI
enzymes and lipid peroxidation
enzymes; and (vi) caspase-11 and caspase-1 act as upstream master regulators, which partially upregulate the expressions of
cytokines,
chemokines, canonical and noncanonical
inflammasome pathway regulators, TI
enzymes, and lipid peroxidation
enzymes. Our findings provide novel insights on the synergies between
hyperlipidemia and hypomethylation in establishing TI and promoting
inflammation in NASH and
NAFLD progression and novel targets for future therapeutic interventions for NASH and
NAFLD,
metabolic diseases,
transplantation, and
cancers.